All In Biotech

Drug Trial Radar · NCT05648357

A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

A Single-arm, Open-label, Multi-center, Phase IV Trial to Evaluate the Reactogenicity, Safety, and Immunogenicity of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India

Last checked: Nov 20, 2026Latest source record: Mar 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

250

Actual

Start

Dec 14, 2023

Primary completion

Feb 26, 2024

Study completion Feb 26, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter \[mL\]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a post-approval condition imposed by the Indian regulatory authorities (CDSCO) for this age group in India.

Conditions

  • Influenza, Human

Interventions

  • Fluarix Tetra VaccineBiological

    A single dose of Fluarix Tetra vaccine administered intramuscularly (IM) on day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Reporting Any Solicited Administration Site Adverse EventTime frame: Day 1 to Day 7
  2. Number of Participants Reporting Any Solicited Systemic EventsTime frame: Day 1 to Day 7
  3. Number of Participants Reporting Unsolicited Adverse Events (AEs)Time frame: Day 1 to Day 21
  4. Number of Participants Reporting Serious Adverse Events (SAEs)Time frame: Day 1 to Day 21

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Belagavi, India

  • GSK Investigational Site

    Kattankulathur, India

  • GSK Investigational Site

    Nashik, India

  • GSK Investigational Site

    Nashik, India

  • GSK Investigational Site

    Varanasi, India

  • GSK Investigational Site

    Visakhapatnam, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.